Condition: Solid Tumor, Adult · Refractory Cancer · Endometrial Carcinoma (EC) · Sponsor: GV20 Therapeutics
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
This description comes directly from the study's public registry record.
GV20 Therapeutics · 617-256-2846 · clinicaltrials@gv20tx.com
Always discuss trial participation with your own doctor first.
| The Angeles Clinic and Research Institute | Los Angeles, California, United States | Recruiting |
| HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Not Yet Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists & Research Institute, LLC | Fort Myers, Florida, United States | Not Yet Recruiting |
| Community Health Network, Inc. | Indianapolis, Indiana, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center | Detroit, Michigan, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Verdi Oncology Tennessee, Scri Oncology Partners | Nashville, Tennessee, United States | Not Yet Recruiting |
| Oncology Consultants, P.A. | Houston, Texas, United States | Recruiting |
| The University of Texas M. D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05669430